FDA Approves Caplyta SNDA With Robust New Data Supporting Reduced Risk of Relapse in Schizophrenia
April 28, 2026
April 28, 2026
RARITAN, New Jersey, April 28 -- Johnson and Johnson Innovative Medicine issued the following news release on April 27, 2026:
* * *
FDA approves CAPLYTA(R) (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia
CAPLYTA(R) reduced relapse risk by 63 percent, with 84 percent of patients with schizophrenia relapse-free over six months
Demonstrating long-term stability and a well-established safety profile cons . . .
* * *
FDA approves CAPLYTA(R) (lumateperone) sNDA with robust new data supporting reduced risk of relapse in schizophrenia
CAPLYTA(R) reduced relapse risk by 63 percent, with 84 percent of patients with schizophrenia relapse-free over six months
Demonstrating long-term stability and a well-established safety profile cons . . .